GRAPPA 2019 Research Recipient Awards Report

Published on Jun 1, 2021in The Journal of Rheumatology3.35
· DOI :10.3899/JRHEUM.201682
Arthur Kavanaugh85
Estimated H-index: 85
,
A. Ishchenko1
Estimated H-index: 1
+ 4 AuthorsSamuel T Hwang49
Estimated H-index: 49
Sources
Abstract
A summary of the research conducted by the recipients of the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Research Awards is presented. Dr. Alla Ishchenko's project was "Role of Metabolomics in Diagnosis, Disease Severity, and Progression in Psoriasis and Psoriatic Arthritis: A 2-year Prospective Pilot Study" and Dr. Zhenrui Shi's project was "Preclinical Analysis of CCR6 and CCL20 in Mouse and Human Joints, Respectively, as Targets of Therapeutic Intervention in Psoriatic Arthritis."
References5
Newest
#1Laura Leys (AbbVie)H-Index: 8
#2Yibing Wang (AbbVie)H-Index: 3
Last. Steve McGaraughty (AbbVie)H-Index: 34
view all 14 authors...
: The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of psoriasis and is elevated in lesional psoriatic skin. Different murine models have been developed to mimic this pathophysiology each carrying specific merits and limitations. In an attempt to address some of these limitations, B10.RIII mice received a single hydrodynamic injection of IL-23 minicircles (MC) to induce hepatic transcription and the endogenous production of IL-23. Plasma and ear IL-23 levels were dose-d...
7 CitationsSource
#1Anthony E. Getschman (MCW: Medical College of Wisconsin)H-Index: 7
#2Yasutomo Imai (Hyogo College of Medicine)H-Index: 15
Last. Brian F. Volkman (MCW: Medical College of Wisconsin)H-Index: 55
view all 8 authors...
Psoriasis is a chronic inflammatory skin disease characterized by the infiltration of T cell and other immune cells to the skin in response to injury or autoantigens. Conventional, as well as unconventional, γδ T cells are recruited to the dermis and epidermis by CCL20 and other chemokines. Together with its receptor CCR6, CCL20 plays a critical role in the development of psoriasiform dermatitis in mouse models. We screened a panel of CCL20 variants designed to form dimers stabilized by intermol...
29 CitationsSource
#1Adrian Y.S. Lee (Menzies Research Institute)H-Index: 10
#2Heinrich Körner (Menzies Research Institute)H-Index: 49
The therapeutic targeting of pro-inflammatory TNF with neutralising biological anti-TNF agents, often in combination with other disease-modifying anti-rheumatic drugs, such as the purine synthesis inhibitor methotrexate has been the first major break-through in the treatment of chronic inflammatory diseases in decades. There are however, side effects and disadvantages of these treatments, such as general immunosuppression as well as therapy resistance in a large proportion of patients. This evok...
45 CitationsSource
#1Iannis E. Adamopoulos (MSD: Merck & Co.)H-Index: 24
#2Marlowe S. Tessmer (MSD: Merck & Co.)H-Index: 12
Last. Edward P. Bowman (MSD: Merck & Co.)H-Index: 30
view all 12 authors...
The role of IL-23 in the development of arthritis and bone metabolism was studied using systemic IL-23 exposure in adult mice via hydrodynamic delivery of IL-23 minicircle DNA in vivo and in mice genetically deficient in IL-23. Systemic IL-23 exposure induced chronic arthritis, severe bone loss, and myelopoiesis in the bone marrow and spleen, which resulted in increased osteoclast differentiation and systemic bone loss. The effect of IL-23 was partly dependent on CD4+ T cells, IL-17A, and TNF, b...
131 CitationsSource
#1Michael N. Hedrick (NIH: National Institutes of Health)H-Index: 6
#2Anke S. Lonsdorf (University Hospital Heidelberg)H-Index: 11
Last. Joshua M. Farber (NIH: National Institutes of Health)H-Index: 60
view all 4 authors...
Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the TH17 subset of CD4+ T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pat...
44 CitationsSource
Cited By2
Newest
#1Esther S. Kim (Springer Science+Business Media)H-Index: 13
#2Susan J. Keam (Springer Science+Business Media)H-Index: 16
Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). In phase 3 trials, once-daily filgotinib was generally well tolerated and associated with an improvement in RA signs and symptoms as well as physical function in patients with an inadequate resp...
Source
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2020 in an online format due to travel restrictions during the coronavirus disease 2019 (COVID­19; caused by SARS-CoV-2) pandemic. The virtual meeting was attended by 351 rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA's annual meeting focused on the 3 overlapping missions of education, res...
Source